We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Dominant Gene Mutations Causes Van der Woude Syndrome

By LabMedica International staff writers
Posted on 01 Jan 2014
A new gene has been identified that is related to the Van der Woude syndrome, the most common syndrome with cleft lip and palate. More...


There are more than 350 syndromes with clefts, of which Van der Woude syndrome (VWS) is the most common and approximately 70% of the individuals with VWS have a mutation in a gene called interferon regulatory factor 6 (IRF6).

An international team led by scientists from the Karolinska Institute (Huddinge, Sweden) collected DNA samples from 45 families of multiple ethnicities who were completely sequenced for IRF6 without identifying a causative mutation. A total of 360 unrelated individuals without a history of oral cleft from the Philippines were used as controls.

The team started by executing a genetic linkage study of a large family from Finland. The family had been diagnosed with VWS, although no IRF6 mutations had been found. By comparing the DNA of affected individuals with DNA from healthy family members, the scientists identified another gene, called Grainy-head like 3 (GRHL3), which was mutated only in the affected family members. The same gene was found to be altered in seven additional families with VWS where no IRF6 mutations had been found previously.

Genomic DNA from eight affected and three healthy individuals from the VWS Finnish family underwent SureSelect Target Enrichment (Agilent Technologies, Santa Clara, CA, USA) in order to perform sequence capture of the exome. Enriched samples were sequenced on an Illumina HiSeq instrument (San Diego, CA, USA). Genotyping, mutation screening by Sanger sequencing, phenotyping, and other studies were also performed. The authors conclude that both genes are required for a proper formation of the palate, probably functioning in separate but convergent molecular pathways. The study highlights the importance of studying even rare patients to increase our understanding of disease mechanisms.

Myriam Peyrard-Janvid, PhD, the senior author of the study said, “The discovery of a new gene, GRHL3, responsible for the most common of the syndromic forms of cleft lip and palate means that clinicians with collections of families or isolated cases with cleft lip and palate, syndromic or non-syndromic, now will be able to look for mutations in this gene. As it has been shown for IRF6, one or several polymorphisms in GRHL3 might be found to be associated with increased risk of clefts in nonsyndromic cases.” The study was published on December 19, 2013, in the American Journal of Human Genetics.

Related Links:

Karolinska Institute
Agilent Technologies
Illumina 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.